This continuous monitoring can lead to better disease management and more timely adjustments in GLP-1 therapy
BPC-157: Proposed to treat ulcerative colitis TB-500: Proposed for wound healing KPV: Proposed for wound healing and inflammatory conditions MOTS-c: Proposed to treat obesity and osteoporosis Semax: Proposed to treat cerebral ischemia (a shortage of blood flow and oxygen to the brain), migraine and trigeminal neuralgia (a chronic pain condition in the face) Epitalon: Proposed to treat insomnia While some peptide experts celebrate this as one step closer to access to life-improving drugs, others claim there isnt enough data on safety and efficacy
Developed to target the cytosolic enzyme nicotinamide N-methyltransferase (NNMT), 5-Amino-1MQ serves as a highly specialized molecular probe designed to study the regulation of energy homeostasis, macromolecular metabolism, and epigenetic signaling networks within mammalian tissue models, particularly white adipose tissue (WAT)
GLP-1 Agonists Show Promise in Treating Substance Use Disorders Nov 7, 2025 5 min read Updated: Dec 17, 2025 In recent years, medications originally developed to treat Type 2 diabetes, obesity, and other weight-related conditionssuch as semaglutide and liraglutideare showing promise in treating substance use disorders (SUDs)